Unidad Clínica de Cuidados Intensivos, Hospital Universitario Virgen Macarena, Sevilla, Spain.
Unidad Clínica de Cuidados Intensivos, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
Med Intensiva (Engl Ed). 2022 Jun;46(6):326-335. doi: 10.1016/j.medine.2022.04.006. Epub 2022 May 8.
The rise of infections caused by multi-resistant gram-negative bacilli (MR-GNB), which includes carbapenems, represents one of the major current challenges worldwide. These MR-GNB include extended spectrum β-lactamase-producing Enterobacterales, derepressed AmpC-producing or carbapenemase-producing Enterobacterales as well as non-fermenting Gram-negative bacilli such as Pseudomonas aeruginosa or Acinetobacter baumannii. P. aeruginosa predominantly exhibits other resistance mechanisms different to β-lactamases such as expulsion pumps or loss of porins. A. baumannii frequently presents several of these resistance mechanisms. Mortality is high especially if empirical treatment is inadequate. In this review, treatment strategies are revised, describing the tools available to identify patients in whom empirical antibiotic treatment would be justified to cover MR-GNB, the importance of optimizing the administration of these antibiotics, as well as prevention strategies to avoid its spread from patients colonized or infected by a MR-GNB.
耐碳青霉烯类革兰氏阴性杆菌(MR-GNB)感染的增加,包括碳青霉烯类抗生素,是目前全球面临的主要挑战之一。这些 MR-GNB 包括产超广谱β-内酰胺酶的肠杆菌科、去阻遏 AmpC 或产碳青霉烯酶的肠杆菌科以及非发酵革兰氏阴性杆菌,如铜绿假单胞菌或鲍曼不动杆菌。铜绿假单胞菌主要表现出不同于β-内酰胺酶的其他耐药机制,如外排泵或孔蛋白缺失。鲍曼不动杆菌经常表现出多种这些耐药机制。死亡率很高,特别是如果经验性治疗不足。在这篇综述中,我们回顾了治疗策略,描述了可用于识别需要经验性抗生素治疗以覆盖 MR-GNB 的患者的工具,以及优化这些抗生素给药的重要性,以及预防策略以避免其从定植或感染 MR-GNB 的患者传播。